News

Photo
08.11.2024 • News

Ascendis Licences Proprietary Technology to Novo Nordisk

Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop, manufacture, and commercialize proprietary products for the treatment of metabolic and cardiovascular diseases.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
06.11.2024 • News

Solenis Completes Acquisition of BASF’s Mining Flocculants Business

US specialty chemicals company Solenis has acquired BASF’s flocculants business for mining applications. With this strategic acquisition, Solenis enhances its portfolio for mining and mineral processing customers. The transaction, for which financial details were not disclosed, was first announced in July.

Photo
05.11.2024 • News

Ardena Expands European Bioanalytical Capabilities

Belgium-headquartered pharmaceutical contract development and manufacturing organization (CDMO) Ardena announced plans to expand its bioanalytical services in the Netherlands. As part of the investment, the company plans to establish a new bioanalytical laboratory at its Pivot Park facility in Oss, as well as additional capacity and new GLP capabilities at its bioanalytical center of excellence in Assen.

Photo
04.11.2024 • News

Secarna Appoints Konstantin Petropoulos as CEO

Germany’s Secarna Pharmaceuticals has appointed Konstantin Petropoulos as CEO. He is stepping up from his previous role as the company’s chief business officer (CBO) and succeeds Alexander Gebauer, who is stepping down with immediate effect to focus his efforts on another company, Galimedix Therapeutics, that he has co-founded and is leading.

Photo
31.10.2024 • News

Kemira to Close Pulp & Paper Chemicals Site at Vancouver

Finnish chemicals company Kemira announced plans to consolidate some of its pulp & paper chemical production in North America, resulting in the closure of a manufacturing site in Vancouver, Canada. The Vancouver site produces process and functional chemicals for the pulp & paper segment.

Photo
31.10.2024 • NewsBioprocessing

Sterling Pharma Solutions Expands GMP ADC Manufacturing Capacity

Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.

Photo
31.10.2024 • News

Renasens - No Waste, Only Resources

The female-led Swedish start-up Renasens has developed a clean, waterless recycling technology that transforms textile waste into valuable new resources.

Photo
31.10.2024 • News

GSK Acquires Lupus Drug Candidate from Chimagen Biosciences

GlaxoSmithKline (GSK) agreed to acquire a clinical-stage drug from Chimagen Biosciences, a privately held Chinese biotechnology company. CMG1A46 is a dual CD19 and CD20-targeted T cell-engager (TCE), which GSK plans to develop and commercialize with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.

Photo
30.10.2024 • News

AbbVie to Buy US Biotech Firm Aliada for $1.4 Billion

US drugmaker AbbVie has signed an agreement to acquire biotechnology company Aliada Therapeutics, which develops therapies for central nervous system (CNS) diseases using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.

Photo
30.10.2024 • News

CEPSA Becomes Moeve

Today, CEPSA announced its name change to Moeve, marking a historic milestone in the company’s transformation. This change positions Moeve as a leader in the European energy transition and demonstrates the significant progress achieved under its 2030 Positive Motion strategy, reinforcing its full commitment to sustainable energy and mobility.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
25.10.2024 • News

Rentschler Plans New Buffer Media Facility at its Headquarters

In a move to further increase production efficiency and modernize the site, German contract development and manufacturing organization (CDMO) Rentschler Biopharma plans to construct a new buffer media station at its company headquarters in Laupheim. According to Rentschler, this is the largest single investment in the German site.

Photo
24.10.2024 • News

TfS Launches Product Carbon Footprint Exchange Platform

With sustainability and carbon reduction high on the global agenda, industries are under increasing pressure to meet decarbonization targets in line with the Paris Agreement. To support companies in the chemical sector in meeting this challenge, Together for Sustainability (TfS), a global sustainability initiative representing more than 50 major chemical companies, has announced the launch of its Product Carbon Footprint (PCF) Exchange solution.

Photo
24.10.2024 • News

Lonza Extends ADC Manufacturing Collaboration with Biopharma Company

Swiss contract development and manufacturing organization (CDMO) Lonza has announced a long-term extension of its collaboration with a key global biopharmaceutical partner for the manufacture of antibody-drug conjugates (ADCs) at commercial scale. The name of the partner was not disclosed.

Photo
23.10.2024 • News

Avantium Opens Biobased FDCA Plant in the Netherlands

Dutch renewables specialist Avantium has officially opened its FDCA (furandicarboxylic acid) flagship plant in Delfzijl, the Netherlands. Plans for what was said to be the world's first commercial-scale production plant for FDCA were first announced in December 2021.

Photo
21.10.2024 • News

Sanofi in Talks to Sell Stake in Opella to CD&R

Sanofi has entered into talks with Clayton Dubilier & Rice (CD&R), a US-based investment company, about the potential sale of a 50% controlling stake in the French drugmaker‘s consumer healthcare business, Opella.

Photo
17.10.2024 • News

Cambrex Opens New Stability Storage Facility

Today, Cambrex announced its stability storage business, Q1 Scientific, and opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to North America's pharmaceutical, medical device, and life sciences industries.

Photo
16.10.2024 • News

Lundbeck to Acquire Longboard Pharmaceuticals

Danish drugmaker Lundbeck has announced to acquire US company Longboard Pharmaceuticals in a deal valued at approximately $2.6 billion. Longboard, headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases.

Photo
15.10.2024 • News

Solvay Completes Major GHG Emissions-Reduction Project in the US

Solvay has inaugurated its regenerative thermal oxidation (RTO) process at its US plant at Green River, Wyoming. The innovative emissions control technology, which Solvay claims is the first of its kind in the trona mining industry, is expected to help reduce greenhouse gas emissions at the plant by up to 20% annually and achieve a 4% reduction in emissions at group level by 2025.

Photo
14.10.2024 • News

Mestag Signs License and Research Deal with Merck & Co.

Mestag Therapeutics, a Cambridge, UK-headquartered biotech company working on new insights into fibroblast-immune interactions, has signed a license and collaboration agreement with US drugmaker Merck & Co., known as MSD outside of North America, to identify novel targets for the development of therapies against inflammatory diseases.

Photo
14.10.2024 • News

Sudarshan Chemical Agrees to Acquire Heubach Group

Sudarshan Chemical Industries Limited (SCIL) recently announced that it has entered into a definitive agreement with the Germany-based Heubach Group, on its acquisition in a combination of an asset and share deal. Sudarshan aims to expand its global presence and pigment portfolio across 19 sites to provide customers with a top-tier product range.

Photo
14.10.2024 • News

Honeywell Plans to Spin Off Its Advanced Materials Business

In a move to progress its strategic priorities of accelerating organic growth, Honeywell announced that it plans to spin off its Advanced Materials business into an independent, US publicly traded company. The spin-off, which is expected to be tax-free to its shareholders, is likely to be completed by the end of next year or early 2026, subject to certain customary conditions.

Photo
11.10.2024 • News

Specialty Pharma CDMO OneSource Recently Launched

OneSource Specialty Pharma, a newly incorporated CDMO, formed from the merger of three CDMO businesses within the Strides Group. The company has a 30-year track record and specializes in biologics, drug-device combinations, and soft gelatin capsules.

Photo
04.10.2024 • News

Piramal to Expand US Facility for Sterile Injectables

US contract development and manufacturing organization (CDMO) Piramal Pharma Solutions (PPS), part of India-headquartered Piramal Pharma, plans to invest $80 million for the expansion of its Lexington, Kentucky, facility.

Photo
03.10.2024 • NewsBioprocessing

Lilly Announces New $4.5 Billion Site

Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.

13365 more News

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.